PISCATAWAY, N.J. — Camber Pharmaceuticals announces the addition of pantoprazole sodium for delayed-release oral suspension to its current portfolio.
Pantoprazole sodium for delayed-release oral suspension is indicated for:
· Short-Term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD) in adults and pediatric patients five years of age and older.
· Maintenance of Healing of Erosive Esophagitis and Reduction in Relapse Rates of Daytime and Nighttime Heartburn Symptoms in adult patients with GERD.
· Long- Term Treatment of Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome.
For more information regarding indications for pantoprazole sodium delayed-release oral suspension please click here.
Pantoprazole Sodium for delayed-release oral suspension is available in cartons of 30 unit dose 40 mg packets.
